Clinical Trials on Active Juvenile Psoriatic Arthritis in Russian Federation

Total 91 results

Biocad

Active, not recruiting

Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis (PATERA)

Psoriatic Arthritis

Russian Federation, Belarus
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Novartis Pharmaceuticals

Active, not recruiting

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis Related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, Spain, United States, Poland
Novartis Pharmaceuticals

Completed

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis-related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, United Kingdom, United States, Spain, Poland
Bristol-Myers Squibb

Completed

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Active Polyarticular Juvenile Idiopathic Arthritis

United States, Spain, Belgium, Italy, Argentina, Brazil, France, Germany, Mexico, Peru, Russian Federation, South Africa
Hoffmann-La Roche

Terminated

An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

Russian Federation, Poland
Novartis Pharmaceuticals

Completed

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement (MAXIMISE)

Axial Psoratic Arthritis

Belgium, Israel, Spain, Switzerland, Greece, Italy, Bulgaria, Germany, Hungary, Estonia, United Kingdom, Poland, France, Czechia, Russian Federation, Romania, Ireland, Finland
AbbVie

Completed

A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®) (PETITE)

Polyarticular Juvenile Arthritis

Russian Federation
AbbVie

Completed

A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation (Adherence)

Spondylarthritis | Psoriatic Arthritis | Ankylosing Spondylitis (AS)

Russian Federation
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
R-Pharm International, LLC
Data Management 365; Federal State Budgetary Educational Institution for Higher... and other collaborators

Withdrawn

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Adult-Onset Still's Disease | AOSD

Russian Federation
Groupe Hospitalier Pitie-Salpetriere

Completed

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. (ReFlaP)

Psoriatic Arthritis

United States, Austria, Brazil, Canada, Estonia, France, Germany, Italy, Romania, Russian Federation, Singapore, Spain, Turkey, United Kingdom
Astellas Pharma Inc
Biogen

Completed

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Psoriatic Arthritis

Poland, Canada, United States, Russian Federation, Germany
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (BE ACTIVE)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis (BE ACTIVE 2)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
Abbott
Almedis; Scientific Research Institute of Rheumatology, Moscow

Completed

Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Russian Federation
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Australia, Czechia, Hungary, Serbia, Slovakia, Estonia, Spain, Russian Federation, Lithuania, Bulgaria
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

United States, Germany, Spain, Poland, Romania, Canada, Russian Federation
Mylan Inc.
Mylan GmbH

Completed

MYL-1401A Efficacy and Safety Comparability Study to Humira®

Psoriasis | Arthritis, Psoriatic

Bulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis

Argentina, Bulgaria, Canada, Finland, France, Germany, Ireland, Italy, Russian Federation, Spain, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Boehringer Ingelheim

Completed

A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

Arthritis, Juvenile Rheumatoid

Belgium, Italy, Germany, Russian Federation, France, Austria, United Kingdom
Sun Pharmaceutical Industries Limited

Completed

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Psoriatic Arthritis

United States, Argentina, Hungary, Mexico, Poland, Russian Federation, Spain, Ukraine
Novartis Pharmaceuticals

Completed

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab (ß-SPECIFIC 4)

Systemic Juvenile Idiopathic Arthritis (SJIA)

Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Pfizer

Completed

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)

Psoriatic Arthritis

United States, Belgium, Spain, Taiwan, Australia, Brazil, Czechia, France, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom
UCB BIOSCIENCES GmbH
PRA Health Sciences

Completed

Pediatric Arthritis Study of Certolizumab Pegol (PASCAL)

Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

United States, Argentina, Brazil, Canada, Chile, Mexico, Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Amgen

Completed

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Psoriatic Arthritis

Spain, Canada, United States, Czechia, Russian Federation, Hungary, Australia, New Zealand, Estonia, Romania
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)

Psoriatic Arthritis

United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Eli Lilly and Company

Completed

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

Psoriatic Arthritis

Spain, Bulgaria, Czechia, Estonia, Mexico, Poland, Ukraine, United States, South Africa, Russian Federation, Slovakia, United Kingdom
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
Hoffmann-La Roche

Completed

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Argentina, Germany, Italy, Russian Federation, Spain, Mexico, Australia, France
Bausch Health Americas, Inc.

Completed

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2)

Psoriatic Arthritis

United States, France, Hungary, Mexico, Poland, Germany, Canada, Greece, Russian Federation, Latvia
Hoffmann-La Roche

Completed

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Juvenile Idiopathic Arthritis

Canada, Mexico, United States, Argentina, Germany, Israel, Italy, Russian Federation, Spain, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Pfizer

Completed

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (OPAL BROADEN)

Psoriatic Arthritis

United States, Canada, Spain, Germany, Australia, Hungary, Belgium, Mexico, Poland, Russian Federation, Taiwan, United Kingdom, Slovakia, Czechia, Bulgaria, France
Bristol-Myers Squibb

Recruiting

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Germany, Mexico, Peru, Russian Federation, Austria, Brazil, Canada, Denmark, France, Greece, Hungary, Israel, Italy, Latvia, Netherlands, Portugal, Puerto Rico, Romania, Saudi Arabia, Slovakia, South Africa, Spain, United...
Sanofi
Regeneron Pharmaceuticals

Completed

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) (SKYPP)

Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Chile, Czechia, Finland, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Spain, United Kingdom
UCB Biopharma SRL

Active, not recruiting

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE VITAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Amgen

Completed

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE2)

Psoriatic Arthritis

United States, Italy, Belgium, France, Canada, Taiwan, United Kingdom, Czechia, Russian Federation, Hungary, Germany, Bulgaria, Estonia, South Africa, Poland, Spain
Amgen

Completed

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Psoriatic Arthritis

United States, Hungary, Czechia, Mexico, Russian Federation, Puerto Rico, Canada, Greece, Poland, Bulgaria, Spain, United Kingdom, Argentina, Latvia, Chile, France, Portugal, South Africa
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1)

Psoriatic Arthritis

Spain, United Kingdom, Estonia, Hungary, India, Italy, Germany, Israel, United States, Australia, Greece, Bulgaria, Lithuania, Korea, Republic of, Portugal, Russian Federation, Netherlands, France, Czechia, Canada, Poland, Slovakia, Denmar... and more

Clinical Trials on Active Juvenile Psoriatic Arthritis in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations